M&A Deal Summary |
|
|---|---|
| Date | 2016-12-29 |
| Target | Apollo Endosurgery |
| Sector | Medical Products |
| Buyer(s) | Apollo Endosurgery |
| Deal Type | Merger |
| Advisor(s) | Piper Sandler & Co. (Financial) Cooley (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2005 |
| Sector | Life Science |
| Employees | 202 |
| Revenue | 77M USD (2022) |
Apollo Endosurgery is a developer of therapeutic antibodies that bind and inhibit bioactive lipids that contribute to disease. The company concluded mid-stage clinical development of drug candidates iSONEP™ (sphingomab) in wet age-related macular degeneration and ASONEP™ (anti-S1P antibody for systemic delivery) in renal cell carcinoma in 2015. Apollo Endosurgery was incorporated in 2005 and is based in Austin, Texas.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Medical Products M&A | 1 of 1 |
| Type: Merger M&A Deals | 1 of 1 |
| State: Texas M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2016 M&A | 1 of 1 |